Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2004-07-06
2008-03-18
Berch, Mark L (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
active
07345171
ABSTRACT:
Disclosed are polymorphs of the isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one,which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.
REFERENCES:
patent: 6936612 (2005-08-01), Barvian et al.
patent: 7208489 (2007-04-01), Barvian et al.
patent: WO 03/062236 (2003-07-01), None
BBC News/Health, Killer Breast Cancer Therapy Hope, Jan. 21, 2006.
Rane, et al., Nature America, vol. 22, pp. 44-52, May 1999.
Blain, et al., J. Biol. Chem., vol. 272, No. 41, 1997, pp. 25863-25872.
Fischer, P., et al., “Recent Advances And New Directions In The Discovery And Development Of Cyclin-Dependent Kinase Inhbitors ,”Current Opinion in Drug Discovery, 2001, 623-634, vol. 4.
Fry, D., et al., “Inhibitors Of cyclin-Dependent Kinases As Therapeutic Agents For The Treatment Of Cancer,”Current Opinion In Oncologic, Endocrine&Matabolic Investigational Drugs, 2000, 40-59, vol. 2, No. 1.
Sielecki, T., et al., “Cyclin-Dependent Kinase Inhibitors: Useful Targets In Cell Cycle Regulation,”Journal of Medicinal Chemistry, 2000, 1-18, vol. 43, No. 1.
Webster, K., et al., “Novel Drugs Targeting The Cell Cycle,”Emerging Drugs, 2000,45-59, vol. 5, No. 1.
Ministerial Order for Lebanese Patent No. 6633, Official Gazette No. 28, Jun. 19, 2003, 4382-4383.
Beylin Vladimar G.
Blackburn Anthony Clyde
Erdman David Thomas
Toogood Peter Laurence
Berch Mark L
Hsu Wendy L.
Jaisle Cecilia M
Warner-Lambert Company LLC
Zielinski Bryan C.
LandOfFree
Isethionate salt of a selective CKD4 inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isethionate salt of a selective CKD4 inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isethionate salt of a selective CKD4 inhibitor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3974398